Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 1;153(6):e2023063064.
doi: 10.1542/peds.2023-063064.

Primary Ciliary Dyskinesia

Affiliations
Review

Primary Ciliary Dyskinesia

Wallace B Wee et al. Pediatrics. .

Abstract

Primary ciliary dyskinesia (PCD) is a rare, genetic disease characterized by dysfunctional motile cilia and abnormal mucociliary clearance, resulting in chronic sino-oto-pulmonary disease, neonatal respiratory distress, subfertility, and organ laterality defects. Over the past 2 decades, research and international collaborations have led to an improved understanding of disease prevalence, classic and variable phenotypes, novel diagnostics, genotype-phenotype correlations, long term morbidity, and innovative therapeutics. However, PCD is often underrecognized in clinical settings and the recent analyses of genetic databases suggest that only a fraction of these patients are being accurately diagnosed. Knowledge of significant advancements, from pathophysiology to the expanded range of clinical manifestations, will have important clinical impacts. These may include increasing disease recognition, improving diagnostic testing and management, and establishing an adequate pool of affected patients to enroll in upcoming clinical therapeutic trials. The objective of this state-of-the-art review is for readers to gain a greater understanding of the clinical spectrum of motile ciliopathies, cutting-edge diagnostic practices, emerging genotype-phenotype associations, and currently accepted management of people with PCD.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES: Drs Davis, Shapiro, and Ferkol are members of the Medical and Scientific Advisory Board for the Primary Ciliary Dyskinesia Foundation; Dr Davis is the principle investigator on a grant funded by ReCode Therapeutics; Dr Ferkol is supported by NIH award TR3860 and funded by a project for ReCode Therapeutics and served as a consultant for Translate Bio and Arrowhead Pharmaceuticals; Drs Ferkol and Shapiro are advisory board members for Parion Sciences and ReCode Therapeutics; Dr Shapiro receives salary support from the Primary Ciliary Dyskinesia Foundation and grant funding from the Chest Foundation; and the other authors have no relevant conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
The relationship between specific genes, ultrastructural defects, nasal nitric oxide, and clinical features in primary ciliary dyskinesia. Low/nml, low or normal; MTD, microtubular disorganization; NR, not reported in literature. a Normal nasal nitric oxide defined as >77 nL per min.

References

    1. Lucas JS, Davis SD, Omran H, Shoemark A. Primary ciliary dyskinesia in the genomics age. Lancet Respir Med. 2020;8(2):202–216 - PubMed
    1. Shapiro AJ, Davis SD, Polineni D, et al. ; American Thoracic Society Assembly on Pediatrics. Diagnosis of primary ciliary dyskinesia. An Official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2018;197(12):e24–e39 - PMC - PubMed
    1. Horani A, Ferkol TW. Understanding primary ciliary dyskinesia and other ciliopathies. J Pediatr. 2021;230:15–22.e1 - PMC - PubMed
    1. Wallmeier J, Nielsen KG, Kuehni CE, et al. . Motile ciliopathies. Nat Rev Dis Primers. 2020;6(1):77. - PubMed
    1. Torgersen J. Situs inversus, asymmetry, and twinning. Am J Hum Genet. 1950;2(4):361–370 - PMC - PubMed

MeSH terms